SCHEMBL3719783

SCHEMBL3719783

Cc1cc(CN2CCN(C(C)C)CC2)ccc1-c1cncc(-c2cc(-c3ccccn3)nc(C(C)(C)O)c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.39
PPARG P37231 1/20 0.39
ABL1 P00519 1/20 0.36
KIT P10721 1/20 0.36
ABL2 P42684 1/20 0.36
HDAC1 Q13547 2/20 0.36
ACVR1 Q04771 1/20 0.35
TGFBR1 P36897 3/20 0.35
PIK3CD O00329 5/20 0.35
PIK3R1 P27986 4/20 0.35
PIK3CA P42336 4/20 0.35
PIK3CB P42338 4/20 0.35
PIK3CG P48736 4/20 0.35
CCND1 P24385 2/20 0.34
CDK6 Q00534 2/20 0.34
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
CDK1 P06493 1/20 0.33
CDK4 P11802 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3715980 0.90 ACVR1 (0.41) RORCABL1KITABL2HDAC1
SCHEMBL3725367 0.83 DRD2 (0.41) RORCABL1KITABL2HDAC1
SCHEMBL3719903 0.82 DRD2 (0.40) RORCHDAC1ACVR1TGFBR1PIK3CD
SCHEMBL3718092 0.80 DRD2 (0.41) ABL1KITABL2TGFBR1PIK3CD
SCHEMBL3716702 0.79 DRD2 (0.40) ABL1KITABL2TGFBR1DRD2
SCHEMBL3806331 0.79 DRD2 (0.40) HDAC1ACVR1TGFBR1PIK3CDPIK3R1
SCHEMBL3723604 0.79 ABL1 (0.46) ABL1KITABL2ACVR1TGFBR1
SCHEMBL3723126 0.77 PIK3CD (0.40) ABL1KITABL2HDAC1ACVR1
SCHEMBL3717439 0.77 DRD2 (0.42) HDAC1ACVR1TGFBR1PIK3CDPIK3R1
SCHEMBL3718273 0.76 DRD2 (0.46) TGFBR1PIK3CDPIK3R1PIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK RORC 163/4885PPARG 494/4885ABL1 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.